Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
United Kingdom James Porter Additional Development Candidates Nuvalent Inc Company Annual Report On Form Prnewswire Nuvalent Inc
Source: prnewswire.com